Last reviewed · How we verify
NCT06018142
Clinical Application of Super-resolution Ultrasound(SR-US) Imaging in Solid Tumors
trial in Neoplasms, Liver in 100 participants. Status unknown.
28 October 2024
Quick facts
| Lead sponsor | Chinese PLA General Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 June 2022 |
| Primary completion | 28 October 2024 |
| Estimated completion | 28 February 2025 |
| Sites | 1 location across China |
Conditions studied
- Neoplasms, Liver — all drugs for Neoplasms, Liver →
- Neoplasms Malignant — all drugs for Neoplasms Malignant →
- Neoplasm Metastasis — all drugs for Neoplasm Metastasis →
- Ultrasound — all drugs for Ultrasound →
Sponsor
Chinese PLA General Hospital
Who can join
Adults 18 to 80, any sex, with Neoplasms, Liver or Neoplasms Malignant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It has well accepted that tumor angiogenesis present aberrant vascular architecture and functional abnormalities, which is associated with tumorigenesis, tumor propagation and progression. By locating, separating and tracking microbubbles, the recently introduced and upgraded Ultrasound Localization Microscopy (ULM) surpassed classical wave diffraction limit. However, the acquisition of structural and functional parameters of microcirculation in vivo for ULM is still confined by the compromise between the resolution and penetration depth. The relatively long acquisition time induced the difficulty of motion correction potentially, which hampers the preclinical to clinical application in organs with distinct tissue motion such as the liver. Therefore, we take the lead in studying human liver lesion microvasculature, which remains a challenge for noninvasive, quantitative and functional intravital imaging especially due to its deep-seated location and strong motion. We developed a Super-resolution Ultrasound (SR-US) imaging technique based on ULM to assess its feasibility of visualizing and quantifying microvasculature in human organs.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Focal liver lesions: multiparametric microvasculature characterization via super-resolution ultrasound imaging.
Zeng QQ, An SZ, Chen CN, Wang Z, et al · · 2024 · cited 7× · PMID 39636384 · DOI 10.1186/s41747-024-00540-3 -
Ultrasound super-resolved hemodynamic estimation in microvessel using physics-informed neural networks and data assimilation.
Liang M, Liu J, Wang H, An S, et al · · 2026 · PMID 41202508 · DOI 10.1016/j.cmpb.2025.109136
Verify or expand the search:
- PubMed search for NCT06018142
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Chinese PLA General Hospital trials
Trials by the same sponsor.
- NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
- NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
- NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
- NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
- NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06018142 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
- Last refreshed: 30 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06018142.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing